92 Chapter 4 Not tested (n=105736) Tested (n=17011) p value Sex, male (%) 56527 (53.5) 9587 (56.4) <0.001 Median age, years (IQR) 69.0 (53.0 to 81.0) 66.0 (52.0 to 79.0) <0.001 Median number of comorbidities (IQR) 1.0 (0.0 to 2.0) 1.0 (0.0 to 2.0) 0.678 Immunocompromised (%) 11694 (12.2) 2297 (14.4) <0.001 Median 4C Mortality score 22 (IQR) 8.0 (5.0 to 11.0) 9.0 (5.0 to 11.0) <0.001 Median clinical frailty (IQR) 4 (2-6) 3 (2-5) <0.001 Median respiratory rate, per minute (IQR) 20.0 (18.0 to 24.0) 21.0 (18.0 to 26.0) <0.001 Temperature, degrees Celsius (mean (SD)) 37.4 (0.91) 37.5 (0.94) <0.001 Median systolic blood pressure, mmHg (IQR) 107 (102 to 116) 108 (102 to 117) 0.101 Median diastolic blood pressure, mmHg (IQR) 63 (56 to 71) 62 (55 to 70) 0.102 Median SaO2 (IQR) 94 (92 to 96) 94 (91 to 96) <0.001 Median FiO2 (IQR) 0.37 (0.29 to 0.60) 0.37 (0.29 to 0.61) <0.001 Critical care admission (%) 16758 (16.4) 4567 (27.6) <0.001 Invasive mechanical ventilation (%) 4882 (4.7) 1747 (10.4) <0.001 In-hospital mortality (%) 19877 (18.8) 3344 (19.7) 0.008 Supplementary table 3: Characteristics of hospitalised people with COVID-19 undergoing testing for additional respiratory viruses. Patients were defined as being immunocompromised if they had received a solid organ transplant, bone marrow or stem cell transplantation in the last 6 months, active chemotherapy, lung cancer with radical radiotherapy, cancer of the blood or bone marrow, immunotherapy for cancer or other targeted cancer treatment that affect the immune system, inborn errors of metabolism (such as severe combined immunodeficiency (SCID) or homozygous sickle cell), HIV positive or used pre-admission immunosuppressive therapy.
RkJQdWJsaXNoZXIy MTk4NDMw